Sintilimab (Tyvyt)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From NCI Drug Dictionary: A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.

Diseases for which it is used

History of changes in NMPA indication

  • 2018-12-24: Initial approval

Also known as

  • Code name: IBI-308
  • Brand names: Daboshu, Tyvyt